|
Terry Colip
Terry Colip, cornerstone of Cell>Point-
The cornerstone of Cell>Pointis metabolic imaging and therapeutic
targeting through nuclear medicine.
The company is developing novel radiopharmaceutical imaging
agents,radiotherapeutic agents and local regional radio/chemotherapeutic drug
delivery systems for the diagnosis, treatment and post therapy assessment of
cancer, cardiovascular disease, infectious diseases and metabolic diseases. Our
mission is to advance radiodiagnostic applications and make quality molecular
imaging available to more people and to create targeted internal
radiotherapeutic agents to improve the treatment for certain forms of cancer and
certain other dibilitatingdiseases. We proudly accept the challenge to make a
difference.
Cell>Point is a privately held biotechnology companyheadquartered in Englewood,
Colorado with offices in Houston, Texas. The company's three technology
platforms, ethylenedicysteine drug conjugate technology ("EC Technology"),
In-Situ Hydrogel radio/chemotherapeutic high yield delivery system ("In Situ
Hydrogel Technology"), and tetraazacyclopentadecane technology ("N4 Technology")
are being developed to create new radiodiagnostic molecular imaging agents to be
imaged with single photon emission computed tomography ("SPECT") cameras and
positron emission tomography ("PET") cameras, new internal radiotherapeutic
agents, and high yield delivery systems for the administration of local regional
radio/chemotherapy to patients with inoperable or surgically nonreseactable
tumors. We believe that nuclear medicine will play an increasingly important
role in the diagnosis and treatment of cancer and other diseases. Only through
nuclear medicine does the radiologist or medical oncologist have the ability to
image and quantify tumor activity and assess other molecular functions. It has
long been the objective of nuclear medicine to identify a highly specific tumor
marker, label it with a diagnostic radioisotope and then substitute it with a
therapeutic radio-active agent to destroy the tumor.ThisisCell>Point's mission.
EC Technology
Developed by scientists at The University of Texas M.D. Anderson Cancer Center
and exclusively licensed to Cell>Pointin 2001, EC Technology is a unique water
soluble chelator technology that possesses exceptional chemical stability, ease
of use and versatility. It is expected that EC Technology will have applications
in oncology, neurology, cardiology and infectious disease.
In the field of oncology, there is a need for better tools to diagnose cancer,
improve patient management and outcome, pre-screen the patient to determine the
best course of therapy, help determine the proper therapeutic dosing level for
each patient and assess patient response to therapy. In the past, radiolabeling
with technetium-99m ("99mTc") was made difficult due to the complexity of
technetium chemistry and the relatively few chelators thatwereavailable.AtCell>Point,
we believe EC Technology will provide a resolution to these issues. 99mTc, as
well as many other diagnostic radioisotopes and radionuclides, can now be
labeled to a wide range of drug conjugate compounds and tissue specific ligands.
Mechanism based target assessment is crucial in cancer therapy. EC Technology
diagnostic agents can assess pharmacological response and biochemical process
thus providing staging, grading, treatment follow-up and assistance in the
selection of patients who should be more responsive to the particular treatment
being considered. The versalitity of EC Technology has been demonstrated in (i)
receptor targeting (EGF, ER, AR, HER 2, LH, somatostatin, transferrin, etc.),
(ii) transcriptional targeting (deoxyglucose, doxorubicin, etc.), (iii) tissue
hypoxia targeting (metronidazole), (iv) apoptosis targeting (annexin V), (v)
vascular targeting (e.g. angiostatin, interferon alpha, colchicine, paclitaxel,
etc.), (vi) gene expression targeting (penciclovir, 5-flurocytidine) and (vii)
enzymatic targeting (cox-2, mmp-2 and mmp-9).
In Situ Hydrogel
In July 2003, the company acquired the exclusive worldwide technology license
and patent rights to In-Situ Hydrogel which will be used for site specific
regional chemotherapy and radiotherapy. By comparison with other hydrogel
technology, In-Situ Hydrogel is unique in that it is capable of delivering a
high yield load dose of a therapeutic radionuclide, such as rhenium-188 (“ 188
Re”), directly to the tumor site without collateral leakage into surrounding
healthy tissue. In addition, In-Situ Hydrogel is capable of delivering a
therapeutic radionuclide and chemotoxic drug simultaneously to treat solid
tumors and surgically unresectable tumors. The absence of post injection leakage
should help the patient avoid the side-effects most often attributable to
standard chemotherapy and external beam radiation treatment. Pre-clinical
studies have demonstrated the potential of In-Situ Hydrogel as an effective high
load yield delivery system. The hydrogel formulation entraps the radionuclide
and/or chemotherapeutic drug at the tumor site immediately following
administration. The radionuclide remains entrapped within the polysaccharide
matrix while the chemotherapeutic drug slowly releases.
Terry
Managing Partner & CFO
Cell>Point, LLC
7120 E. Orchard Rd., Suite 355
Centennial, Colorado 80111
www.cellpointweb.com
(303) 689-9693
|